【Youth Daily】 Hyundai Biosciences succeeded in developing’Poly-COV01′, an injection for the treatment of severe patients with novel coronavirus infection (Corona 19), by C&Pharm, the major shareholder, and emergency use approval with DT&CRO, a clinical consignment organization (CRO), etc. It was announced on the 23rd that it had signed a clinical agency contract for
‘Poly-COV01′ is an oral or nasal inhaler among corona19 patients like’Feramivir’, an injection that emerged as the last hope of severely ill patients who were unable to take the oral drug’Tamiflu’, which was injured as a game changer during the 2009 H1N1 flu crisis. It was developed by C&Pharm for very few severely ill patients who could not even administer it.
C&Pharm’s’Poly-COV01′ is a drug that improves the short half-life of the blood concentration of nikolasamide based on its’pain-free anticancer drug’ platform, and by controlling the number of administrations, virus proliferation is 100% throughout the treatment period. It was developed with the aim of maintaining’IC100′, which is an effective concentration in the blood to be suppressed, and it is characterized by minimizing side effects due to drug toxicity.
Niclosamide, the base drug of’Poly-COV01′, was selected as the No. 1 candidate for COVID-19 treatment among major drugs in the world by Institut Pasteur Korea in April of this year, and it can be applied to various diseases such as cancer and diabetes in addition to corona virus diseases. Known in
C&Pharm expects’Poly-COV01′ to be the last’hopeful injection’ for severely ill patients with Corona 19 currently at the crossroads of life and death, and under the policy of conducting the clinical procedure of’Poly-COV01′ as quickly as possible, The schedule for testing the efficacy of injections is being discussed.
An official at Hyundai Bio said, “We will first supply’Poly-COV01′ to the severely ill patients who are further driven into the blind spot of treatment due to the third coronavirus pandemic, so that they can administer’Poly-COV01′ prior to marketing approval from the authorities. We are pushing ahead.”
【Youth Daily = Reporter Ahn Sang-jun】